alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### § 15.202 Certified operating frequency range.

Client devices that operate in a master/client network may be certified if they have the capability of operating outside permissible part 15 frequency bands, provided they operate on only permissible part 15 frequencies under the control of the master device with which they communicate. Master devices marketed within the United States must be limited to operation on permissible part 15 frequencies. Client devices that can also act as master devices must meet the requirements of a master device. For the purposes of this section, a master device is defined as a device operating in a mode in which it has the capability to transmit without receiving an enabling signal. In this mode it is able to select a channel and initiate a network by sending enabling signals to other devices. A network always has at least one device operating in master mode. A client device is defined as a device operating in a mode in which the transmissions of the device are under control of the master. A device in client mode is not able to initiate a network.

[70 FR 23040, May 4, 2005]
Exhibit








 Exhibit 10.3
2017 Annual Base Salaries


	
			
	Executive Officer
	Prior Base Salary
	2017 Base Salary

	Douglas C. Bryant
President and Chief Executive Officer
	$558,846
	$574,846

	Michael D. Abney, Jr.
Senior Vice President, Distribution
	$334,780
	$352,780

	Robert J. Bujarski
Senior Vice President, Business Development and General Counsel
	$362,759
	$372,759

	Werner Kroll
Senior Vice President, Research and Development
	$350,127
	$372,000

	Edward K. Russell
Senior Vice President, Global Commercial Operations
	$362,708
	$372,708

	Randall J. Steward
Chief Financial Officer
	$365,058
	$375,058
eworld_ex103.htm

EXHIBIT 10.3

 

 

Trademark Office of The State Administration For Industry & Commerce of the People's Republic of China

 


	Address: No. 1, South Chama St, Xicheng Qu, Beijing	Zip Code: 100055



 


	
9550 Flair Dr. #308

 



El Monte, Ca 91731

 



E-World USA Holding, Inc.

 
	

	
File Number:

 



TMCZ20669799ZCSL01

 




 


	
Application Date: July 15, 2016 
	
Application No: 20669799




 


	
Trademark Registration Application Acceptance Notice



E-World USA Holding, Inc:

 



According to <Trademark Law> and <Regulation for the Implementation of the Trademark>, we received and accept your application as below.

 



Category: Fifth

 



Hereby Notice.

 





September 25, 2016




 

Shenzhen Qianna Patent Agency LTD.

 

Notice: This notice only indicates the trademark office has already received the application of the said trademark, but not for approval of the trademark registration.

 

Current page/Total Pages: 1/1

  

[The notice of Acceptance of Trademark, trademark can be used, After registration, it can add R]
1 

### Schaeffer, John

From: Lin, Chuantung

Sent: Thursday, February 27, 2014 10:29 AM

To: Schaeffer, John; Brooks, David; Boethling, Bob; Townsend, Mark

Cc: Lewis, Paul; Mattheisen, Mike; Njo, Heat her; Williamson, Tracy; Christian, Myrta Subject: RE: Test Data for 5026-74-4 HPV3_FW: Regulat ions.gov [ Your scheduled notification: ]



### Hi John,

I have reviewed the submitted test data and related test methods for the P/Chem properties of - Oxiranemethanamine, N-[4-(2-oxiranylmethoxy)phenylJ -N-(2-oxiranylmethyl)-(CAS No. 5026-74-4). The followings are ICB's comments for this review:

1) The test data and the methods used to obtain the data are adequate and acceptable to EPA for this HPV3 test chemical. Although the submitted data include other endpoints test results that were not required by the HPV3 test rules for A1,A2, A3, A4 and A5. All these additional data and test methods (for Density, Flash Point, Auto-ignition temperature, Oxidizing properties, and Oxidizing properties, Hydrolysis as a function of PH, Adsorption coefficient (Koc), Dissociation cons tant, and Viscosity) were adequate and acceptable to EPA. Particularly, the hydrolysis half-life rate of 2.3 days at 25°C & pH 7 is was an important data for the Fate

assessment.

2) For the Melting Point endpoint , the sponsor of this HPV3 test chemical obtain a "freezing point" value of - 39.42°C. The test substance was a liquid form at the room temperature. Therefore, the sponsor of this test substance should indicate that the freezing point data was used to substitute for the melting point endpoint (A1).

3) For the Boiling Point (B.P.) endpoint, the sponsor indicated the test substance has no boiling temperature for this endpoint but indicated that the test substance decomposed at ~250°C and above. Therefore, the decomposition temperature should be used to fulfill the data gap for the HPV3 test rule requirement for the B.P. endpoint (A2)

.

4) For the n-Octanol/Water Partition Coefficient (log Kow) , the sponsor of this test substance did not provide a test result (data) and methodology for this endpoint. The sponsor of this test substance needs to test and provide a data for this endpoint to fulfill the HPV3 test rule requirement (A4)

.

5) The submitted data and test methods (protocols) for Vapor Pressure (V.P.) and Water Solubility endpoints were acceptable. The test substance has a hydrolysis half-life rate of 2.3 days at 25°C & pH 7 (see ICB’s comment #1, above)

Please let me know if you have any question on this matter.

Daniel

‐‐‐‐‐ Original Message ‐‐‐‐‐ From: Schaeffer, John

Sent: Wednesday, February 26, 2014 8:31 AM

To: Brooks, David; Boethling, Bob; Townsend, Mark; Lin, Chuantung

Cc: Lewis, Paul; Mattheisen, Mike; Njo, Heather Subject: FW: Test Data for 5026

‐ 74

‐ 4 HPV3_FW: Regulations.gov [ Your scheduled notification:

Daniel, Dave & Bob
TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

NO. 03-10-00180-CV

In re Paul Christian Velte

ORIGINAL PROCEEDING FROM HAYS COUNTY

M E M O R A N D U M O P I N I O N

PER CURIAM

This petition for writ of mandamus is denied. See Tex. R. App. P. 52.8(a).

Before Chief Justice Jones, Justices Pemberton and Waldrop

Filed: April 9, 2010
{"version":"1.0","provider_name":"U.S. Court of Appeals for the Federal Circuit","provider_url":"https:\/\/cafc.uscourts.gov","author_name":"25005pwpadmin","author_url":"https:\/\/cafc.uscourts.gov\/author\/25005pwpadmin\/","title":"18-2345: SPITZ TECHNOLOGIES CORPORATION v. NOBEL BIOCARE USA, LLC [RULE 36 JUDGMENT], Nonprecedential - U.S. Court of Appeals for the Federal Circuit","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"7AXBFB8DRz\"><a href=\"https:\/\/cafc.uscourts.gov\/7-15-2019-18-2345-spitz-technologies-corporation-v-nobel-biocare-usa-llc-rule-36-judgment-18-2345-rule_36_judgment-7-15-2019-1\/\">18-2345: SPITZ TECHNOLOGIES CORPORATION v. NOBEL BIOCARE USA, LLC [RULE 36 JUDGMENT], Nonprecedential<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/cafc.uscourts.gov\/7-15-2019-18-2345-spitz-technologies-corporation-v-nobel-biocare-usa-llc-rule-36-judgment-18-2345-rule_36_judgment-7-15-2019-1\/embed\/#?secret=7AXBFB8DRz\" width=\"600\" height=\"338\" title=\"“18-2345: SPITZ TECHNOLOGIES CORPORATION v. NOBEL BIOCARE USA, LLC [RULE 36 JUDGMENT], Nonprecedential” — U.S. Court of Appeals for the Federal Circuit\" data-secret=\"7AXBFB8DRz\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Opinions\/Orders posted: SPITZ TECHNOLOGIES CORPORATION v. NOBEL BIOCARE USA, LLC [RULE 36 JUDGMENT](pdf) Appeal Number: 18-2345 Origin: DCT Nonprecedential To see more opinions and orders, follow this link: Opinions and Orders."}
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Antitrust Division

                    Notice is hereby given that, on March 31, 2000, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301*et seq.*                     (“the Act”), Die Products Consortium (DPC) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership status. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Agilent Technologies, Inc., Palo Alto, CA; and IBM, Armonk, NY have been added as parties to this venture.                

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Die Products Consortium (DPC) intends to file additional written notification disclosing all changes in membership.

                    On November 15, 1999, Die Products Consortium (DPC) filed its original notification pursuant to section 6(a) of the Act. A notice has not yet been published in the                     **Federal Register**                    .                

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 00-16480  Filed 6-28-00; 8:45 am]

BILLING CODE 4410-11-M
**Exhibit 31.1**

**CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT**

I, Robert Vrij, certify that: 

1. I have reviewed this quarterly report on Form 10-Q of Openwave Systems Inc.; 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of theregistrant as of, and for, the periods presented in this report; 

4. The registrant’s other certifying officer and I areresponsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) forthe registrant and have: 

a) Designed such disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in whichthis report is being prepared; 

b) Designed such internal control over financial reporting, or caused such internalcontrol over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generallyaccepted accounting principles; 

c) Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during theregistrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting whichare reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. 

Date: November 8, 2007
###### Editorial Note on Part 1

#### Editorial Note:

Nomenclature changes to part 1 appear at 63 FR 54077, Oct. 8, 1998.

#### § 1.297 Oral argument.

Oral argument with respect to any contested interlocutory matter will be held when, in the opinion of the person(s) who is to make the ruling, the ends of justice will be best served thereby. Timely notice will be given of the date, time, and place of any such oral argument.

[29 FR 6444, May 16, 1964]
Editorial Note on Part 1
Editorial Note: Nomenclature changes to part 1 appear at 63 FR 54077, Oct. 8, 1998.

§ 1.1119 Petitions and applications for review. ( a ) The fees established by this subpart may be waived or deferred in specific instances where good cause is shown and where waiver or deferral of the fee would promote the public interest.
( b ) Requests for waivers or deferrals will only be considered when received from applicants acting in respect to their own applications. Requests for waivers or deferrals of entire classes of services will not be considered.
( c ) Petitions for waivers, deferrals, fee determinations, reconsiderations and applications for review will be acted upon by the Managing Director with the concurrence of the General Counsel. All such filings within the scope of the fee rules shall be filed as a separate pleading and clearly marked to the attention of the Managing Director. Any such request that is not filed as a separate pleading will not be considered by the Commission. Requests for deferral of a fee payment for financial hardship must be accompanied by supporting documentation. ( 1 ) Petitions and applications for review submitted with a fee must be submitted electronically or to the Commission's lock box bank at the address for the appropriate service as set forth in §§ 1.1102 through 1.1107.
( 2 ) If no fee payment is submitted, the request should be filed electronically through the Commission's Electronic Comment Filing System or with the Commission's Secretary.
( d ) Deferrals of fees will be granted for an established period of time not to exceed six months.
( e ) Applicants seeking waivers must submit the request for waiver with the application or filing, required fee and FCC Form 159, or a request for deferral. A petition for waiver and/or deferral of payment must be submitted to the Office of the Managing Director as specified in paragraph (c) of this section. Waiver requests that do not include these materials will be dismissed in accordance with § 1.1111 of this subpart. Submitted fees will be returned if a waiver is granted. The Commission will not be responsible for delays in acting upon these requests.
( f ) Petitions for waiver of a fee based on financial hardship will be subject to the provisions of paragraph 1.1166(e).
[52 FR 5289, Feb. 20, 1987, as amended at 55 FR 19172, May 8, 1990; 55 FR 38065, Sept. 17, 1990. Redesignated and amended at 59 FR 30998, June 16, 1994, as further amended at 59 FR 30999, June 16, 1994. Redesignated at 60 FR 5326, Jan. 27, 1995, as amended at 65 FR 49762, Aug. 15, 2000; 66 FR 36202, July 11, 2001; 67 FR 67337, Nov. 5, 2002; 68 FR 48467, Aug. 13, 2003. Redesignated and amended at 74 FR 3445, Jan. 21, 2009; 83 FR 2556, Jan. 18, 2018]
No. 11-5288.

#### Greenawalt *v.*Warren, Warden.

C. A. 6th Cir. Certiorari denied.
nhmd_ex41.htm

EXHIBIT 4.1

 

AMENDMENT NO. 1

 

TO THE

 

NATE’S FOOD CO.

 

2014 STOCK INCENTIVE PLAN 

 

WHEREAS, Nate’s Food Co. (the "Company") has adopted the 2014 Stock Incentive Plan of the Company (the “Plan”) (capitalized terms used but not defined herein shall have the meaning ascribed thereto in the Plan);

 

WHEREAS, pursuant to Article XI of the Plan, the Board of Directors of the Company (the “Board”) and under certain circumstances, a majority of the shareholders of the Company, may amend or terminate the Plan as may be necessary or desirable to implement or discontinue the Plan or any provision thereof;

 

WHEREAS, the Board and the majority shareholders have determined it is advisable and in the best interest of the Company and its stockholders to amend the Plan by increasing the number of shares authorized for issuance under the Plan to 50,000,000 shares of common stock, par value 0.0001 per share;

 

WHEREAS, the Board now desires to amend the Plan to increase the number of shares authorized for issuance under the Plan (the “Amendment”);

 

NOW, THEREFORE, the Plan is hereby amended as follows:

 

1. Section 3.4 of the Plan is hereby amended to read in its entirety as follows:

 

3.4 Subject to the provisions of Section 3.9, the maximum aggregate number of shares of Common Stock which may be issued pursuant to Awards under the Plan shall be Fifty Million (50,000,000) shares. Such shares of Common Stock shall be made available from authorized and unissued shares of the Company.

 

2. This Amendment shall be effective as of the date this Amendment is authorized and approved by the Board.

 

3. Except to the extent hereinabove set forth, the Plan shall remain in full force and effect.

 

[- Signature Page Follows -]



	 
	1

	


	 



 

IN WITNESS WHEREOF, this Amendment is heretofore executed by a duly authorized officer of the Company on this 29th day of December, 2016.

 


		
NATE’S FOOD CO.

				
		
By: 
	
/s/ Nate Steck
	
		
Name: 
	
Nate Steck
	
		
Title: 
	
President
	



 

[- Signature Page to Amendment to Plan -]

 


	
2
<PAGE>

EXHIBIT 99.2

                           NATIONAL AUTO CREDIT, INC.
                  CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
                           PURSUANT TO 18 U.S.C. 1350
                 (SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

I, Robert V. Cuddihy, Jr., Chief Financial Officer of National Auto Credit,
Inc., a Delaware corporation (the "Registrant"), in connection with the
Registrant's Annual Report on Form 10-K for the year ended January 31, 2003, as
filed with the Securities and Exchange Commission on the date hereof (the
"Report"), do hereby represent, warrant and certify pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

     (1) The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and

     (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Registrant.


/s/ Robert V. Cuddihy, Jr.
--------------------------------------------
Name: Robert V. Cuddihy, Jr.
Title: Chief Financial Officer
Date:  April 25, 2003
79 

80 

    -       - Superintendent of Documents
      - 2010-12-23T16:23:30-0500
      - US GPO, Washington, DC 20401
      - Superintendent of Documents
      - GPO attests that this document has not been altered since it was disseminated by GPO
# AGENCY:

 National Aeronautics and Space Administration (NASA) 

# SUMMARY:

 The National Aeronautics and Space Administration, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995 (Pub. L. 104-13, 44 U.S.C. 3506(c)(2)(A)). Information collection is required to ensure proper use of and disposition of rights to inventions made in the course of, and data developed under NASA contracts. 

# DATES:

 All comments should be submitted on or before March 27, 2000. 

# ADDRESSES:

 All comments should be addressed to Mr. Phillip Smith Code BFZ, National Aeronautics and Space Administration, Washington, DC 20546-0001. 

# FOR FURTHER INFORMATION CONTACT:

 Ms. Carmela Simonson, NASA Reports Officer, (202) 358-1223. 

*Title:*                        NASA Contractor Financial Management Reports                     

*OMB Number:*                        2700-0003                     

*Type of review:*                        Extension                     

*Need and Uses:*                        The NASA Contractor Financial Management Reporting System is the basic financial medium for contractor reporting of estimated and incurred costs, providing essential data for projecting costs and hours to ensure that contractor performance is realistically planned and supported by dollar and labor resources. The data provided by these reports is an integral part of the Agency's accrual accounting and cost-based budgeting systems required under 31 U.S.C. 3512.                     

*Affected Public:*                        Business or other for-profit, not-for-profit institutions.                     

*Number of Respondents:*                        850.                     

*Responses Per Respondent:*                        12.                     

*Annual Responses:*                        10,200.                     

*Hours Per Request:*                        9 hrs.                     

*Annual Burden Hours:*                        91,500.                     

*Frequency of Report:*                        quarterly/monthly.                     

David B. Nelson, 

Deputy Chief Information Officer, Office of the Administrator. 

[FR Doc. 00-1669 Filed 1-24-00; 8:45 am] 

BILLING CODE 7510-01-U